These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31853136)

  • 41. `Risk of cardiovascular disease associated with febuxostat versus allopurinol use in patients with gout: a retrospective cohort study in Korea.
    Jeong H; Choi E; Suh A; Yoo M; Kim B
    Rheumatol Int; 2023 Feb; 43(2):265-281. PubMed ID: 36346443
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
    Gupta MK; Singh JA
    Drugs; 2019 Apr; 79(5):531-541. PubMed ID: 30868398
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in kidney transplant recipients.
    Tojimbara T; Nakajima I; Yashima J; Fuchinoue S; Teraoka S
    Transplant Proc; 2014; 46(2):511-3. PubMed ID: 24656001
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comment on: Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis.
    Deng JH; Zhang JX
    Clin Cardiol; 2022 Jul; 45(7):685-686. PubMed ID: 35634752
    [No Abstract]   [Full Text] [Related]  

  • 45. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lesinurad: A Review in Hyperuricaemia of Gout.
    Deeks ED
    Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Inhibitors of xanthine oxidoreductase].
    Okamoto K
    Nihon Rinsho; 2008 Apr; 66(4):748-53. PubMed ID: 18409526
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Class effect of xanthine oxidase inhibitors on flow-mediated dilatation in hypertensive patients: A randomized controlled trial.
    Hoshide S; Kabutoya T; Ueno H; Kario K
    J Clin Hypertens (Greenwich); 2020 Mar; 22(3):451-456. PubMed ID: 31873985
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.
    Xu S; Liu X; Ming J; Chen S; Wang Y; Liu X; Liu H; Peng Y; Wang J; Lin J; Ji H; Liu B; Lu Y; Liu P; Zhang Y; Ji Q
    Int J Rheum Dis; 2015 Jul; 18(6):669-78. PubMed ID: 26013187
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta-analysis.
    Deng JH; Lai PH; Xie LS; Qiu SS; Qiu DS; Zhang JX
    Clin Transl Sci; 2024 Mar; 17(3):e13757. PubMed ID: 38488426
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Febuxostat: a new treatment for hyperuricaemia in gout.
    Edwards NL
    Rheumatology (Oxford); 2009 May; 48 Suppl 2():ii15-ii19. PubMed ID: 19447778
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Response to: 'Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the artcile by Singh and Clevland' by Quills
    Singh JA
    Ann Rheum Dis; 2022 Jul; 81(7):e125. PubMed ID: 32616606
    [No Abstract]   [Full Text] [Related]  

  • 53. Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment.
    Bardin T; Chalès G; Pascart T; Flipo RM; Korng Ea H; Roujeau JC; Delayen A; Clerson P
    Joint Bone Spine; 2016 May; 83(3):314-7. PubMed ID: 26709250
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Correspondence to 'Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data'.
    Ma KS; Wei JC; Chung WH
    Ann Rheum Dis; 2022 Jun; 81(6):e107. PubMed ID: 32561605
    [No Abstract]   [Full Text] [Related]  

  • 55. Urate-lowering therapy for gout: focus on febuxostat.
    Love BL; Barrons R; Veverka A; Snider KM
    Pharmacotherapy; 2010 Jun; 30(6):594-608. PubMed ID: 20500048
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014-2017.
    Weisshaar S; Litschauer B; Reichardt B; Gruber F; Leitner S; Sibinovic S; Kossmeier M; Wolzt M
    Rheumatol Int; 2022 Sep; 42(9):1597-1603. PubMed ID: 35589988
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Febuxostat Use and Safety in Patients With Hyperuricemia.
    Kawada T
    J Rheumatol; 2022 Oct; 49(10):1180. PubMed ID: 35705244
    [No Abstract]   [Full Text] [Related]  

  • 58. Successful Desensitization to Febuxostat in a Patient With Hypersensitivity to Allopurinol and Febuxostat and Review of the Literature.
    Koenig D; Royer C; Azar A
    J Clin Rheumatol; 2021 Dec; 27(8S):S432-S433. PubMed ID: 31977653
    [No Abstract]   [Full Text] [Related]  

  • 59. Inappropriate prescription of allopurinol and febuxostat and risk of adverse events in the elderly: results from the REPOSI registry.
    Pasina L; Brucato AL; Djade CD; Di Corato P; Ghidoni S; Tettamanti M; Franchi C; Salerno F; Corrao S; Marengoni A; Marcucci M; Mannucci PM; Nobili A;
    Eur J Clin Pharmacol; 2014 Dec; 70(12):1495-503. PubMed ID: 25228251
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Febuxostat, a potential drug in the secondary prevention of cardiovascular disease with hyperuricemia.
    Xu C; Meng J
    Int J Cardiol; 2023 Jan; 370():367. PubMed ID: 36306952
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.